| Name | Title | Contact Details |
|---|
Quotient Sciences is a drug development and manufacturing accelerator supporting customers from candidate selection to commercial launch.
TwelveStone is focused on the medication needs of patients with complex and chronic conditions. For more than 35 years, TwelveStone has been dedicated to finding new ways to deliver care designed around the patient. Chronic conditions include Multiple Sclerosis, Cystic Fibrosis, Hemophilia, Crohn`s Disease, Growth Deficiency, HIV, Leukemia, and many others. For patients, we provide access to the most advanced medications, along with the personal and financial support patients need to live with chronic conditions. For providers, we simplify treatment for complex conditions by eliminating the administrative and clinical burdens placed on your practice when patients need innovative specialty medication. Providers we serve: • Hospitals • Long-Term Care • Hospice • Home Care • Specialty Clinics Solutions include: • MEDIpack-Medication made simple, efficient, and accurate • Infusion & Enteral Services- Home infusion, infusion services, and infusion centers • Respiratory Equipment -In partnership with AeroCare From comprehensive medication support to peer advocates and a team of pharmacy support professionals, TwelveStone Health Partners supports the transition from acute to post-acute care environments and the journey from sickness to health. We are currently licensed in 30 states: Alaska, Arizona, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky, Louisiana, Maine, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, North Carolina, North Dakota, New York, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Washington, Wisconsin and Wyoming.
Alpine Solutions is a pioneer in the medical industry for the repair and sales of electronics, imaging equipment, CT & MRI parts, medical drives and etc.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.